Clinical Research Directory
Browse clinical research sites, groups, and studies.
Shrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal Cavity
Sponsor: Hai-Qiang Mai,MD,PhD
Summary
This is a an open-label, non-inferiority, multicenter, randomized phase III trial aimed to explore the efficacy and safety of shrinking the anterior border of CTV2 in nasopharyngeal carcinoma patients without tumor invasion into the posterior nasal aperture.
Official title: Shrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal Cavity : an Open-label, Non-inferiority, Multicenter, Randomized Phase III Trial
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
550
Start Date
2025-08-01
Completion Date
2032-07-31
Last Updated
2025-07-18
Healthy Volunteers
No
Conditions
Interventions
standard CTV delineation
The anterior border of CTV2 is delineated at the posterior 1/3 of the nasal cavity.
reduced CTV delineation
The anterior border of CTV2 is defined as 5 mm anterior to the posterior nasal cavity anteriorly from the choanae.
Locations (5)
First People's Hospital of Foshan
Foshan, Guangdong, China
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Affiliated Hospital of Guangdong Medical University
Zhangjiang, Guangdong, China
The Fourth Affiliated Hospital of Guangxi Medical University
Liuchow, Guangxi, China
Wuzhou Red Cross Hospital
Wuzhou, Guangxi, China